These Analysts Revise Their Forecasts On Biogen After Q1 Results
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday.
Biogen reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion, according to data from Benzinga Pro.
Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Rare disease revenue decreased 4% year over year (down 4% CC) to $423.9 million. Spinraza's revenue fell to $341.3 million from $443.3 million a year ago.
For the fiscal year 2024, Biogen reaffirms adjusted EPS Of $15.00-$16.00 versus consensus of $15.48, up around 5% versus 2023 at the mid-point. The company expects 2024 total revenue to decline by a low- to mid-single-digit percentage, with operating income expected to grow at a low-double-digit percentage.
Biogen shares gained 4.6% to close at $201.99 on Wednesday.
These analysts made changes to their price targets on Biogen following earnings announcement.
- HC Wainwright & Co. cut the price target on Biogen from $325 to $300. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating.
- Wedbush boosted the price target on Biogen from $213 to $215. Wedbush analyst Laura Chico maintained a Neutral rating.
- Needham analyst Ami Fadia, meanwhile, reiterated Biogen with a Buy and maintained a $294 price target.
Read More: Jefferies Financial, Maplebear And 2 Other Stocks Insiders Are Selling
Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday.
百健公司（納斯達克股票代碼：BIIB）週三公佈的第一季度收益好於預期。
Biogen reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion, according to data from Benzinga Pro.
Biogen報告稱，第一季度調整後每股收益爲3.67美元，增長8％，超過市場普遍預期的3.44美元。根據Benzinga Pro的數據，該公司公佈的銷售額爲22.9億美元，同比下降7％，未達到23.1億美元的共識。
Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Rare disease revenue decreased 4% year over year (down 4% CC) to $423.9 million. Spinraza's revenue fell to $341.3 million from $443.3 million a year ago.
多發性硬化症收入爲11億美元，下降了4％（按固定匯率下降4％）。多發性硬化症藥物Tysabri的銷售額從4.728億美元降至4.313億美元。罕見病收入同比下降4％（下降4％），至4.239億美元。Spinraza的收入從去年同期的4.433億美元降至3.413億美元。
For the fiscal year 2024, Biogen reaffirms adjusted EPS Of $15.00-$16.00 versus consensus of $15.48, up around 5% versus 2023 at the mid-point. The company expects 2024 total revenue to decline by a low- to mid-single-digit percentage, with operating income expected to grow at a low-double-digit percentage.
對於2024財年，百健重申調整後的每股收益爲15.00美元至16.00美元，而市場預期爲15.48美元，與2023年中點相比增長約5％。該公司預計，2024年的總收入將下降低至中等的個位數百分比，營業收入預計將以兩位數的低百分比增長。
Biogen shares gained 4.6% to close at $201.99 on Wednesday.
週三，百健股價上漲4.6％，收於201.99美元。
These analysts made changes to their price targets on Biogen following earnings announcement.
業績公佈後，這些分析師更改了Biogen的目標股價。
- HC Wainwright & Co. cut the price target on Biogen from $325 to $300. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating.
- Wedbush boosted the price target on Biogen from $213 to $215. Wedbush analyst Laura Chico maintained a Neutral rating.
- Needham analyst Ami Fadia, meanwhile, reiterated Biogen with a Buy and maintained a $294 price target.
- HC Wainwright & Co. 將百健的目標股價從325美元下調至300美元。HC Wainwright & Co. 分析師安德魯·費恩維持買入評級。
- Wedbush將Biogen的目標股價從213美元上調至215美元。Wedbush分析師勞拉·奇科維持中性評級。
- 與此同時，尼德姆分析師阿米·法迪亞重申了Biogen的買入，並維持了294美元的目標股價。
Read More: Jefferies Financial, Maplebear And 2 Other Stocks Insiders Are Selling
閱讀更多：傑富瑞金融、Maplebear和其他兩隻股票內部人士正在賣出
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧